Arteriocyte Research & Development Focused on Improving Patient Outcomes 
Corporate Homepage

Protein Co-delivery

Arteriocyte's development of a novel protein delivery technology via intra-cellular placement is intended to increase the integrated angiogenic signaling in ischemia. The result is anticipated to be a synergistic angiogenic response without the challenges of unregulated growth signaling. The company's protein co-delivery technology is currently in pre-clinical development.

 


  Arteriocyte, Inc.

  Locations:

  Ohio Offices
  Cleveland
  Research & Development Center
  7100 Euclid Avenue
  Cleveland, Ohio 44103, USA
  Phone: 216-456-9640
 

  Massachusetts Offices
  Hopkinton
  Eastern US Manufacturing
  and Distribution Center
  45 South Street
  Hopkinton, MA 01748, USA
  Phone: 508-497-8950

  Utah Offices
  Salt Lake City
  Tissue Engineering Center
  1413 Center Drive, Ste 220
  Park City, UT 84098, USA
  Phone: 866-660-2674

  Maryland Offices
  Towson
  Malaria Initiative Center
  400 East Joppa Road
  Suite 416
  Towson, MD 21286, USA
  Phone: 866-660-2674

  E-mail: info@arteriocyte.com
  Phone: 1-866-660-AMSI(2674)
  Fax: 1-216-456-9641